| Identification | Back Directory | [Name]
Danicamtiv | [CAS]
1970972-74-7 | [Synonyms]
MYK-491
SAR 440181
Danicamtiv
Danicamtiv (MYK-491)
Inhibitor,allosteric,cardiac,function,inhibit,Myosin,Danicamtiv,acto-myosin,inotropic,systolic,MYK 491,MYK491
1-Piperidinecarboxamide, 4-[(1R)-1-[[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]sulfonyl]-1-fluoroethyl]-N-3-isoxazolyl- | [Molecular Formula]
C16H20F3N5O4S | [MOL File]
1970972-74-7.mol | [Molecular Weight]
435.42 |
| Chemical Properties | Back Directory | [Boiling point ]
699.1±55.0 °C(Predicted) | [density ]
1.57±0.1 g/cm3(Predicted) | [solubility ]
DMSO:50.0(Max Conc. mg/mL);114.83(Max Conc. mM) | [form ]
A solid | [pka]
13.32±0.40(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency[1]. | [in vivo]
Danicamtiv selectively enhances cardiac actomyosin activity, the molecular force‐generating unit of the sarcomere, prolonging contraction while preserving actin–myosin detachment, allowing relaxation, and without impacting Ca2+ homeostasis[2]. | [References]
[1] Sarah Fernandes, et al. Abstract 15707: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation. 2019;140:A15707
[2] Voors AA, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649-1658. DOI:10.1002/ejhf.1933 |
|
|